[go: up one dir, main page]

PE20010579A1 - Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos - Google Patents

Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos

Info

Publication number
PE20010579A1
PE20010579A1 PE2000000894A PE0008942000A PE20010579A1 PE 20010579 A1 PE20010579 A1 PE 20010579A1 PE 2000000894 A PE2000000894 A PE 2000000894A PE 0008942000 A PE0008942000 A PE 0008942000A PE 20010579 A1 PE20010579 A1 PE 20010579A1
Authority
PE
Peru
Prior art keywords
mesoprogestines
modulars
components
progesterone receptor
female contraceptives
Prior art date
Application number
PE2000000894A
Other languages
English (en)
Inventor
Walter Elger
Kristof Chwalisz
Gerd Schubert
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20010579A1 publication Critical patent/PE20010579A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE MESOPROGESTINAS DE 1 mg A 25mg, TAMBIEN SE REFIERE AL USO CON UN ESTROGENO COMO ETINILESTRADIOL, UTILIZANDOSE 10µg A 30µg, ESTRADIOL, ESTER ESTRADIOL, 3-SULFAMATO DE 17ß-ETINILESTRADIOL, 17ß-ESTRADIOL. LA COMPOSICION SE FORMULA PARA LA ADMINISTRACION ORAL O COMO SISTEMA INTRAUTERINO ANTICONCEPTIVO FEMENINO PARA PROVOCAR Y MANTENER LA AMENORREA
PE2000000894A 1999-08-31 2000-08-31 Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos PE20010579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
PE20010579A1 true PE20010579A1 (es) 2001-06-04

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000894A PE20010579A1 (es) 1999-08-31 2000-08-31 Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos

Country Status (28)

Country Link
EP (1) EP1605949A2 (es)
JP (1) JP2003511399A (es)
KR (1) KR20020038745A (es)
CN (1) CN1384748A (es)
AR (1) AR025455A1 (es)
AU (1) AU781835B2 (es)
BG (1) BG106441A (es)
BR (1) BR0013711A (es)
CA (1) CA2383650A1 (es)
CO (1) CO5190694A1 (es)
CZ (1) CZ2002707A3 (es)
EA (1) EA006805B1 (es)
EE (1) EE200200103A (es)
HR (1) HRP20020265A2 (es)
HU (1) HUP0202515A3 (es)
IL (1) IL148415A0 (es)
LT (1) LT5001B (es)
LV (1) LV12940B (es)
MX (1) MXPA02002186A (es)
NO (1) NO20020998L (es)
NZ (1) NZ517470A (es)
PE (1) PE20010579A1 (es)
PL (1) PL353994A1 (es)
SI (1) SI20853A (es)
SK (1) SK2982002A3 (es)
UA (1) UA77150C2 (es)
WO (1) WO2001026603A2 (es)
YU (1) YU13902A (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ES2273061T3 (es) * 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
AR049707A1 (es) * 2004-07-07 2006-08-30 Wyeth Corp Regimenes y kits de progestina ciclica
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
JP5951480B2 (ja) * 2009-04-14 2016-07-13 ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ オンデマンド避妊方法
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
HU214598B (hu) * 1987-09-24 1998-04-28 Jencap Research Ltd Eljárás fogamzásgátló és hormonterápiához alkalmazható, ösztrogént és progesztint tartalmazó gyógyszerkészítmények előállítására
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429398C2 (de) 1994-08-09 1997-09-11 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
PL319869A1 (en) * 1994-10-24 1997-09-01 Schering Ag Competitiveprogesterone antagonists for first-need oriented female fertility control
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
ES2174265T3 (es) * 1996-06-25 2002-11-01 Akzo Nobel Nv Regimenes de progestogeno-anti-progestogeno.
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1175422A2 (en) * 1999-05-04 2002-01-30 Ligand Pharmaceuticals Incorporated Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
BG106441A (bg) 2002-09-30
KR20020038745A (ko) 2002-05-23
MXPA02002186A (es) 2002-09-02
PL353994A1 (en) 2003-12-15
JP2003511399A (ja) 2003-03-25
WO2001026603A2 (en) 2001-04-19
HRP20020265A2 (en) 2004-02-29
LT2002035A (lt) 2002-10-25
AU3215001A (en) 2001-04-23
LV12940B (en) 2003-06-20
NO20020998L (no) 2002-03-14
AR025455A1 (es) 2002-11-27
CZ2002707A3 (cs) 2002-11-13
HUP0202515A2 (hu) 2002-12-28
EP1605949A2 (en) 2005-12-21
EA200200284A1 (ru) 2002-10-31
IL148415A0 (en) 2002-09-12
EA006805B1 (ru) 2006-04-28
NO20020998D0 (no) 2002-02-28
UA77150C2 (en) 2006-11-15
CN1384748A (zh) 2002-12-11
CA2383650A1 (en) 2001-04-19
AU781835B2 (en) 2005-06-16
CO5190694A1 (es) 2002-08-29
BR0013711A (pt) 2002-05-07
EE200200103A (et) 2003-04-15
LT5001B (lt) 2003-03-25
WO2001026603A3 (en) 2002-01-17
SK2982002A3 (en) 2002-07-02
YU13902A (sh) 2006-01-16
SI20853A (sl) 2002-10-31
NZ517470A (en) 2004-03-26
HUP0202515A3 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
CY1108093T1 (el) Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
BRPI0512991A (pt) uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
AR011480A1 (es) ACIL-ANILIDAS SUSTITUIDAS CON RADICALES (HETERO) CICLICOS, NO ESTEROIDALES, CON ACTIVIDAD GESTÁGENA Y ANDRoGENA MIXTA.
CY1116520T1 (el) Φαρμακοτεχνικη μορφη fulvestrant
AU560487B2 (en) Contraceptive comprising gestodene and ethinylestradiol
BRPI0116793B8 (pt) produtos de hormônio de esteróide e métodos para prepará-los
AP9801384A0 (en) Improvements of implantation rates after in vitro fertilization.
ATE244567T1 (de) Kit zur kontrazeption bei weiblichen säugern, bestehend aus einer kombination von gestagen und estrogen
ES2061672T3 (es) Preparado hormonal y su uso.
ECSP084358A (es) NUEVAS FORMAS SÓLIDAS DE LA MESOPROGESTINA 11ß-[4E-(HIDROXIIMINOMETIL)-FENIL]- 17ALFA-METOXIMETIL-17ß-METOXI-ESTRA-4,9-DIEN-3-ONA
PE20060127A1 (es) Sistema de entrega de farmacos constituido por copolimero de polietileno acetato de vinilo
DE122007000011I1 (de) Feste Arzneiformen, enthaltend Clathrate vom steroidalen Sexualhormon Ethinylestradiol
ES2132645T3 (es) Uso en una composicion farmaceutica.
MX2022012917A (es) Composiciones anticonceptivas con efectos adversos reducidos.
PE20010579A1 (es) Mesoprogestinas (modulares de receptores de progesterona) como componentes de anticonceptivos femeninos
CO5631449A2 (es) Nuevos esteres de etonogestrel
BR9911344A (pt) Composto, undecanoato de ment, uso do mesmo, formulação farmacêutica, e, kit para a contracepção masculina.
ECSP055629A (es) COMPOSICIÓN QUE CONTIENE UN ESTEROIDE 11ß-HALOGENADO ANDRÓGENO Y UN GESTÁGENO ASÍ COMO UN CONTRACEPTIVO MASCULINO SOBRE LA BASE DE ESTAS COMPOSICIONES
DE60017281D1 (de) Nomegestrol acetat und estrogen enthaltende zusammensetzung und ihre verwendung
Hahn et al. The pharmacological profile of norgestimate, a new orally active progestin
BR0013769A (pt) Esteróides estrogênicos não aromáticos, composição farmacêutica, e, uso de um composto esteróide
CU23414B7 (es) Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
IT1154735B (it) Derivati d'amino-14 steroidi e procedimento per la loro preparazione
Nutting et al. Anabolic-androgenic activity of A-ring modified androstane derivatives. Part I: A comparison of parenteral activity
ES2148742T3 (es) Dibenz(a,f)azulenos sustituidos y procedimientos de preparacion.

Legal Events

Date Code Title Description
FC Refusal